Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,049 INR | -1.06% | +1.49% | +22.95% |
Apr. 29 | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.95% | 3.59B | |
+20.00% | 43.67B | |
+20.67% | 22.51B | |
+14.56% | 14.6B | |
+13.81% | 13.74B | |
+42.74% | 11.91B | |
-8.37% | 7.04B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.21% | 5.42B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Nomura Downgrades Glenmark Pharmaceuticals to Neutral From Buy, Adjusts Price Target to INR841 From INR633